Biotech | April 04, 2025
Wacker collaborates with RNAV8 Bio to enhance mRNA therapeutics development
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
The demand in Africa for COVID-19 vaccines has declined
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
The companies plan to start a pivotal Phase 3 trial in the coming months
Subscribe To Our Newsletter & Stay Updated
